Send to

Choose Destination
Kidney Int. 2016 Apr;89(4):897-908. doi: 10.1016/j.kint.2016.02.001.

The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis.

Author information

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Pathology Service, Massachusetts General Hospital, Boston, Massachusetts, USA.
Department of Pathology and Laboratory Medicine, Gundersen Health System, La Crosse, Wisconsin, USA.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address:


Classic anti-glomerular basement membrane (GBM) disease presents with rapidly progressive glomerulonephritis (GN) with or without pulmonary hemorrhage. On biopsy typical disease displays bright polytypic linear GBM staining for IgG by immunofluorescence and diffuse crescentic/necrotizing GN on light microscopy. Here, we studied 20 patients with atypical anti-GBM nephritis typified by bright linear GBM staining for immunoglobulins but without a diffuse crescentic phenotype. Patients had hematuria, proteinuria, and mild renal insufficiency, without pulmonary hemorrhage. Light microscopy showed endocapillary proliferative GN in 9 patients, mesangial proliferative GN in 6, membranoproliferative GN in 3, and focal segmental glomerulosclerosis with mesangial hypercellularity in 2. Eight of the 20 showed features of microangiopathy. Crescents/necrosis were absent in 12 and were focal in 8 patients. Bright linear GBM staining for IgG was seen in 17 patients, IgM in 2, and IgA in 1 patient, which was polytypic in 10 patients and monotypic in 10 patients. No circulating α3NC1 antibodies were detected by commercial ELISA. The 1-year patient and renal survival rates were 93% and 85%, respectively. Thus, atypical anti-GBM nephritis is a rare variant of anti-GBM disease characterized clinically by an indolent course, no pulmonary involvement, and undetectable circulating α3NC1 antibodies. Further studies are needed to characterize the molecular architecture of GBM autoantigens in these patients and establish optimal therapy.


anti-GBM disease; glomerulonephritis; kidney biopsy; nephrotic syndrome; renal pathology

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center